Skip to main content
. Author manuscript; available in PMC: 2016 Jan 22.
Published in final edited form as: Neuroscience. 2014 Oct 24;0:555–565. doi: 10.1016/j.neuroscience.2014.10.033

Figure 7.

Figure 7

Region-specific neuroprotection observed with GluN2B antagonist Co 101244. (A.) Quantification of Purkinje cell density measured using calbindin antibody at 7 days after CA/CPR in vehicle (saline), MK-801 (1 mg/kg) and Co101244 (3 mg/kg) treated mice. Dotted line represents Purkinje cell density in sham controls. (B.) Quantification of injury to CA1 neurons at 7 days after CA/CPR in vehicle (saline), MK-801 (1 mg/kg) and Co101244 (3 mg/kg) treated mice. N= 5-12. Comparisons were made using One-way ANOVA with Dunnett’s post-hoc analysis (* p<0.05).